99 articles - From Friday Nov 07 2025 to Friday Nov 14 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Gastrointest Endosc |
|---|
| Establishing Standards of Practice for Transoral Outlet Reduction: An Expert Consensus using a Modified Delphi Method.
These standards provide step-by-step TORe guidance for safe and effective clinical outcomes. |
| Hepatology |
| Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
Non-response may be suspected if ALT or NITs worsen. Benefit is uncertain if sub-optimal response and may require an individualized approach and further follow-up. |
| J Hepatol |
| EASL Clinical Practice Guidelines on vascular diseases of the liver.
Multidisciplinary management involving hepatologists, haematologists, pathologists, interventional radiologists and surgeons is essential in this area. Our aim is to provide guidance on the management of patients with vascular liver diseases based on the best available evidence. |
meta-analyses and systematic reviews
| Gastrointest Endosc |
|---|
| Identifying the Optimal Bowel Prep for Small-Bowel Capsule Endoscopy: A Meta-Review and Umbrella Meta-Analysis.
This study demonstrates that purgative bowel preparation, particularly with PEG, is superior to fasting alone in improving adequate SB cleansing and diagnostic accuracy. Notably, a same-day regimen significantly enhances both cleansing quality and DY, suggesting that the timing of administration is more critical than the laxative's dosage. |
| Gut |
| HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
Peg-IFN add-on results in HBsAg loss in 18% of patients with SOT HBsAg<1000 IU/mL, and in 38% if SOT HBsAg<100 IU/mL. Among patients with higher HBsAg levels, peg-IFN could be used to reduce HBsAg to below thresholds associated with response to novel compounds. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
| A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
ED cancer incidence has not changed among those with IBD but has declined among matched controls. Beyond 2010, ED cancer incidence is higher among those with IBD and cancer-related mortality is higher among those with CD, relative to matched controls. |
| Clin Gastroenterol Hepatol |
| Features and outcomes of 280 patients with idiosyncratic drug-induced liver injury: the REFHEPS prospective study.
REFHEPS registry collected 322 cases in 2.5 years. The study of the 280 idiosyncratic DILI cases shows sex and age-related differences as reported in previous registries. The most significant difference compared to older registries is the predominance of anticancer drugs causing liver injury, demonstrating the emergence of "new" side effects associated with the use of innovative therapies, especially immune checkpoint inhibitors. |
| High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism among Patients with Gastroesophageal Reflux Disease.
A large proportion of patients with GERD who underwent CYP2C19 genotyping were rapid metabolizers of CYP2C19 and responded well to changing/adjusting PPIs accordingly. |
| Novel Machine-Learning Models Outperform Non-Invasive Tests in MASH with Fibrosis.
Novel ML models significantly improve the detection of MASH F2-F3 and cirrhosis over existing NITs and address a key diagnostic gap in the FDA-defined treatment window. These tools may support patient selection for emerging therapies, as well as for clinical trial enrolment. |
| Endosc Int Open |
| Effect of a distal attachment cuff on adenoma detection rate in screening colonoscopy: Randomized controlled trial in the Spanish population.
EV did not improve either ADR or MAP. EV may increase difficulty of ileal intubation whenever it is attempted. |
| Image-enhanced endoscopy improves visibility of endoscopic images in individuals with color vision deficiency.
IEE improves visibility of objects/lesions where color information plays a role in detection, regardless of CVD. |
| Optimizing self-expandable metallic stent placement for malignant ileocecal obstruction: Role of pre-stenting contrast enema and device selection.
SEMS placement in the ileocecal region is technically more challenging than in other right-sided segments. Procedure optimization - potentially aided by CLEAN, tapered hoods, and experienced operators-may help overcome anatomical difficulties while maintaining safety. |
| Prophylactic clipping prevents delayed bleeding after endoscopic mucosal resection of large non-ampullary duodenal lateral spreading lesions.
PC of the resection site significantly reduced DB after EMR of large non-ampullary duodenal lateral spreading lesions. |
| Reduction of greenhouse gas emissions using the endoscope with a light-emitting diode light source.
We estimated the effect of reducing carbon dioxide emissions using the light-emitting diode endoscope system. Wider adoption of the light-emitting diode endoscope system is expected to contribute to usefulness of endoscopic diagnosis and reduction in environmental impact. |
| Risk factors for dysplastic lesions in the proximal stomach in patients with familial adenomatous polyposis.
Carpeting fundic gland polyposis, biliary reflux, and use of PPIs were identified as putative risk factors for dysplastic lesions in the proximal stomach. Presence of these risk factors should alert endoscopists to assess the stomach more thoroughly. |
| Endoscopy |
| Performance measures for endoscopic ultrasound: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative - Update 2025.
The European Society of Gastrointestinal Endoscopy (ESGE) recommends that endoscopy services across Europe adopt the following six key performance measures for endoscopic ultrasound (EUS) for monitoring and evaluation in daily practice at center and endoscopist level: (1: ) informed patient consent (100 % of procedures); (2: ) adequate documentation of landmarks (≥ 90 % of procedures); (3: ) structured training and supervision for trainees, preferably using assessment tools (≥ 20 %); (4: ) standardized description of pancreatic cystic lesions (≥ 85 %); (5: ) diagnostic tissue acquisition with EUS-guided fine-needle aspiration/fine-needle biopsy for solid lesions (≥ 85 %); (6: ) adverse events (< 5 % in cystic and < 3 % in solid lesions). A recommendation to administer antibiotics for EUS-guided puncture of cystic lesions, included in the previous ESGE quality improvement document, has been omitted in the current version based on recent evidence. |
| Role of anti-reflux mucosal ablation in "reflux-predominant" refractory gastro-esophageal reflux disease patients - a randomized sham controlled trial.
ARMA significantly improves symptoms, AET, and reflux episodes in "reflux predominant" PPI-refractory GERD. |
| Gastroenterology |
| Retraction Notice to: "A Rare Cause of Peri-esophageal Cystic Lesion": Gastroenterology 2023;164:191-193.
As such, this article represents a misuse of the scientific publishing system. The Publisher reached out to the authors for an explanation, but they did not respond. |
| The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease.
In MASLD patients with F3/F4, the noninvasive ANTICIPATE-NASH models provide better risk stratification of clinical events than histologic classification. These models could be very useful for clinical trials by selecting patients at risk of clinical events and patients with higher chances of observed cirrhosis regression. |
| Gastrointest Endosc |
| Clinical Characteristics and Outcomes of Patients Managed without Repeat Endoscopic Resection for Metachronous Esophageal Squamous Neoplasia.
For select patients with metachronous ESCN, repeat ER may not be feasible due to lesion complexity or systemic conditions. Adopting personalized treatment strategies that balance safety and efficacy is essential for optimal long-term management. |
| Comparative Safety and Efficacy of Remimazolam versus Propofol for ERCP with the patient Under Deep Sedation: A Multi-center Randomized Controlled Trial.
Remimazolam is a safe and effective alternative to propofol for sedation during ERCP, demonstrating comparable sedation efficacy, higher patient satisfaction, reduced injection site pain, and fewer moderate-to-severe cardiopulmonary adverse events. Remimazolam thus has strong clinical utility, particularly in patients at a higher risk of sedation-related complications. |
| Efficacy of Splinting Tube-Assisted Duodenoscope Insertion in Patients with an Inaccessible Major Papilla: A Single-Center Retrospective Study (with video).
Splinting tube-assisted duodenoscope insertion is a safe and effective troubleshooting technique for difficult insertion into the descending limb of the duodenum. |
| Endoscopic versus Surgical Management of Recurrent Weight Gain Following Sleeve Gastrectomy.
Endoscopic revision of SG appears to be associated with similar weight loss compared to surgical revision or conversion to Roux-en-Y gastric bypass, with a better safety profile. |
| Impact of a sustainability intervention on the carbon footprint and processing expenses of endoscopic waste.
The sustainability intervention demonstrated a meaningful impact, with education and the adoption of sustainable practices - namely waste segregation and recycling - leading to reductions in carbon footprint, waste management costs, and overall waste generation. |
| Precipitation-based versus filtration-based liquid-based cytology in EUS-FNB specimens of solid pancreatic masses: a prospective, randomized trial.
For EUS-guided FNB of solid pancreatic masses, the SurePath™ LBC technique demonstrated superior diagnostic performance, faster interpretation times, and better preservation of cytomorphological features than ThinPrep®. These findings suggest that SurePath™ should be the preferred LBC method for evaluating EUS-guided FNB of pancreatic masses. |
| Gut |
| Engineered virus-hunter vaccine overcomes HBV immune tolerance.
This innovative HBV vaccine strategy actively captures viruses, overcoming the tolerogenic immune microenvironment of chronic HBV infection, offering a novel strategy for the treatment of chronic HBV infection and other immune-tolerant diseases. |
| Indole-3-propionic acid links gut dysfunction to diabetic retinopathy: a biomarker and novel therapeutic approach.
Nutraceutical strategies that restore Trp metabolism or IPA serve as both a biomarker and a treatment for DR. |
| Hepatology |
| A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.
Treatment with rego/pembro is feasible in patients with advanced HCC with a manageable safety profile. ORR and DCR are promising and consistent with other immunotherapy combinations in this setting. |
| Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus Immunotherapy and targeted therapy in HCC.
An imaging radiomic biomarker capturing both global and intratumoral heterogeneity robustly predicts response and survival in HCC patients treated with TACE-ICI-MTT, and reflects underlying immune microenvironment phenotypes. |
| Development and validation of a non-invasive score for at-risk metabolic dysfunction-associated steatohepatitis in individuals with obesity undergoing bariatric surgery.
-The FMO is an accurate and cost-effective non-invasive score for at-risk MASH identification in populations with obesity. |
| GPC3-based circular RNA vaccine suppresses hepatocellular carcinoma progression by activating adaptive immune responses.
The circGPC3 cancer vaccine was demonstrated superior efficacy compared to mRNA cancer vaccine. When further combined with a TLR4 agonist, it disrupted immune tolerance in HCC, offering a promising translational treatment strategy for HCC. |
| Hepatic ischemia reperfusion injury: Underlying mechanisms and concepts in liver surgery and liver transplantation.
Emerging therapeutic strategies, including machine perfusion technologies, ischemic preconditioning, pharmacological interventions and others, offer promise for mitigating H-IRI by either attenuating early injury triggers, enhancing intrinsic survival pathways, or restraining excessive inflammatory responses. Despite considerable progress in understanding H-IRI, further research is needed to identify additional therapeutic targets, particularly in the context of ECD livers, to develop effective, targeted interventions that can improve clinical outcomes. |
| Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study.
In this large global biopsy-based MASLD cohort, advanced fibrosis was highly prevalent and strongly linked to T2D. Both histologic fibrosis and NITs were independent predictors of mortality and clinical outcomes, underscoring the prognostic value of fibrosis assessment with non-invasive tests. |
| J Hepatol |
| An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC.
These findings reveal etiology-heterogeneous immune landscapes in HCC and identify FABP4 as a potential prognostic biomarker to guide immunotherapy in MASLD-related HCC. Impact and implications This study systematically analyzed the impact of HBV, MASLD, and their coexistence on the response and outcomes of immunotherapy in HCC. By integrating single-cell sequencing of patient samples, it highlights the importance of etiological heterogeneity, particularly from the perspective of CD8 + T cells. The study identifies FABP4 as being highly expressed in MASLD-related HCC and implicates it in promoting vascular normalization and CD8 + T cell infiltration. Most importantly, FABP4 emerges as a potential prognostic biomarker for HCC, especially in MASLD-related cases, offering a practical tool to identify patients who are more likely to benefit from immunotherapy. |
| DNAJ-PKAc induces metabolic rewiring and enhanced glutamine flux in fibrolamellar HCC.
The presence of DNAJ-PKAc creates a vulnerability to the combination of glutamine antimetabolite and ICI therapy in FLC. Impact and implications The DNAJ-PKAc fusion in fibrolamellar carcinoma (FLC) induces metabolic reprogramming including enhanced glutamine metabolism, which promotes immune evasion. Targeting this metabolic vulnerability with a glutamine antagonist, in combination with immune checkpoint inhibitors, reverses the immunosuppressive tumor microenvironment (TME), offering a promising therapeutic strategy for FLC treatment. |
| Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.
REP treatment was safe and effective in HDV patients with ACLD. REP may even induce HDV sustained virological response and HBV functional cure independent of combination with pegIFN. Clinical benefits may also be observed in patients with decompensated cirrhosis. Impact and implications No antiviral treatment is approved for chronic hepatitis D (CHD) patients with decompensated cirrhosis or in patients who have failed previous bulevirtide and/or pegIFN therapy. In the Replicor Compassionate Access Program including 33 CHD patients with advanced chronic liver disease treated with REP2139-Mg (REP) and nucleotide analog, with or without pegylated interferon, loss of HBsAg was observed in 27% by end of treatment and remained undetectable in 18% after one year follow up, inferring HDV sustained virological response and HBV functional cure for these patients. Among the 6 patients with decompensated cirrhosis, five patients had virological response and two patients presented significant clinical improvement with ascites reduction, with no REP-related serious adverse events. Overall, the efficacy of REP, in this "difficult to treat" population, appears promising with acceptable tolerability and no safety issues and should be evaluated in a protocol driven, response-guided clinical trial. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
| Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non-Lean Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. |
| Review Article: The Evolving Role of GLP-1 Receptor Agonists in Gastroenterology Practice.
Glucagon-like peptide-1 receptor agonists are a critical therapy for obesity and several related gastrointestinal conditions. Gastroenterologists are uniquely positioned to optimize their use, manage adverse events, coordinate multidisciplinary care, and ensure safe and effective integration into practice. |
| Gut |
| Gut microbiome in IBD: past, present and the future.
Advances in sequencing technologies, multiomics integration and experimental approaches have shed new insights into host-microbiota interactions in IBD and characterised mechanisms through which the microbiota and its metabolites contribute to disease. We review the evolution of microbiome-based research, with a focus on genetic and environmental factors affecting the gut microbiota, the role of cross-kingdom microbiome and their bioproducts in disease development and new strategies by which microbiome-based approaches can be used to diagnose, monitor, prevent and treat IBD. |
| J Hepatol |
| Editorial: HES V2.0: Advancing biomarker-based surveillance for HCC - Promise and remaining gaps. |
| Phase 2 Clinical Trials in Primary Sclerosing Cholangitis: Making the Most of Every Opportunity? |
| RePARylating biliary tumours to improve the efficacy of chemoimmunotherapy. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Clin Gastroenterol Hepatol |
|---|
| Comparable 12-Week and Superior 24-Week Remission with Risankizumab vs Ustekinumab for Crohn's-Like Disease of the Pouch. |
| Dupilumab Improves Multiple Aspects of Dysphagia Symptoms in a Randomized Trial of Eosinophilic Esophagitis. |
| Glucagon-Like Peptide-1 Receptor Agonist Use is Associated With and May Lead To Esophageal Motility Abnormalities. |
| Lifting Agent Granuloma Mimicking Recurrent Gastric Cancer after Endoscopic Submucosal Dissection. |
| Validation of a Novel Laryngopharyngeal Reflux Risk Prediction Score for Proximal and Pharyngeal Reflux on Objective Testing. |
| WEIGHT GAIN FOLLOWING PERORAL ENDOSCOPIC MYOTOMY (POEM) FOR ACHALASIA IS ASSOCIATED WITH POST-POEM GASTROESOPHAGEAL REFLUX DISEASE. |
| Endosc Int Open |
| Balloon occlusion method using a commercially available ileus tube during endoscopic full-thickness resection: Simple solution to gas leakage. |
| Endoscopic full-thickness resection of a gastrointestinal stromal tumor using a double-endoscope snare technique. |
| Endoscopy |
| A case of secondary lymphangiectasia due to ancylostoma intestinal infection. |
| A novel 19-gauge integrated electrocautery-puncture needle for endoscopic ultrasound-guided biliary drainage. |
| A novel closure technique for a mucosal defect after endoscopic submucosal dissection: "closure on traction using a rotatable clip with a line loop". |
| A novel tailored biliary stent with a controllable cover. |
| A self-made wire snare used in combination with a long transparent cap to remove an obstructive sigmoid fecalith. |
| Active appendiceal bleeding recorded by choledochoscopy. |
| Application of gallbladder-cholangial plastic stent with a retraction thread in the treatment of acute calculous cholecystitis: the first clinical practice. |
| Clinical utility of long cap-assisted hemostasis in acute lower gastrointestinal bleeding: two cases. |
| Difficult bile-duct stones in surgical anatomy managed with entero-endoscopic retrograde cholangiopancreatography and a new slim cholangioscope. |
| Endoscopic balloon tamponade for massive bleeding from aorto-esophageal fistula: a simple technique for rapid hemostasis. |
| Endoscopic resection of a giant duodenal lipoma: a case report. |
| Endoscopic retrograde direct cholangioscopy extracting stones from common bile duct in a case of ectopic duodenal papilla. |
| Endoscopic suture therapy for iatrogenic pharyngeal laceration: an extended application of endoluminal surgery. |
| Endoscopic ultrasound-guided coil embolization combined with cyanoacrylate injection into perforating vein for gastric varices. |
| Endoscopic ultrasound-guided enterocolostomy for small bowel obstruction following radical cystectomy with ileal neobladder reconstruction. |
| Endoscopic ultrasound-guided short-cut jejunojejunostomy within a long biliary limb post pancreaticoduodenectomy to facilitate endoscopic retrograde cholangiography. |
| Hybrid side-by-side and stent-in-stent deployment of three slim multi-hole metallic stents for malignant hilar biliary obstruction. |
| Observation and cholangioscopic biopsy of resectable gallbladder cancer using a new ultra-slim cholangioscope. |
| Safe internalization of external cholecystostomy drain by endoscopic ultrasound-guided drainage using a lumen apposing metal stent with endoscopic clipping. |
| Successful endoscopic retrograde appendicitis therapy for acute appendicitis using a multi-side-hole conical cap. |
| Ultrasound-guided treatment of giant isolated gastric varices with gastric-renal shunt using coil, cyanoacrylate, and titanium clips. |
| Underwater endoscopic retrograde direct cholangioscopy facilitating biliary cannulation of intradiverticular duodenal papilla. |
| Wound closure after endoscopic submucosal dissection of the colon using a novel detachable traction device: a rubber ring with a figure-of-eight sliding knot. |
| Gastroenterology |
| Beneficial effects of physical exercise on anticancer immunity are mediated by gut microbiome metabolites. |
| Gut |
| Diabetes and pancreatic cancer: a complex and confounding interplay. |
| Introducing <i>Gut Science-</i>a fundamental and discovery science companion journal to <i>Gut</i>. |
| Thrombospondin-2: a promising but unproven biomarker for MASH. |
| Hepatology |
| 2025 Late Breaking Abstracts. |
| Introducing Saul J. Karpen, MD, PhD, the 77th President of AASLD. |
| Letter to the Editor: Comments on the Study: Body size disparities limit women's access to liver transplantation under the MELD 3.0 scoring system. |
| Letter to the Editor: From risk alert to decision support: Enhancing the clinical value of the AI model for cholangiocarcinoma. |
| Metabolic reprogramming in macrophages: A glutamine rescue in β-catenin mutant hepatocellular carcinoma. |
| Reply: From risk alert to decision support: Enhancing the clinical value of the AI Model for cholangiocarcinoma. |
| Reply: Survival analysis pitfalls in MASLD: Proportional hazards, immortal time, and follow-up discrepancies. |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non-Lean Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease-Authors' Reply. |
| Letter on 'Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis'. |
| Letter on 'Unveiling Drug-Induced Autoimmune-Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study'. |
| Letter: From Descriptive Epidemiology to Clinical Imperative-Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease. |
| Letter: From Descriptive Epidemiology to Clinical Imperative-Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease. Authors' Reply. |
| Letter: Methodological Caveats in Zhang et al.-Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension. |
| Letter: Refining Mortality Estimates in Severe Alcohol-Associated Hepatitis-Addressing Heterogeneity and Prognostic Assessment. |
| Letter: Refining Mortality Estimates in Severe Alcohol-Associated Hepatitis-Addressing Heterogeneity and Prognostic Assessment. Authors' Reply. |
| Gastroenterology |
| The Prospects of MEK Inhibitors in the Treatment of Gastric Precancerous Lesions. |
| Gastrointest Endosc |
| Abandoning random biopsies after Barrett's eradication: a cost-prohibitive inefficiency. |
| Adenoma Detection Rate Alone Is a One-Note Symphony. |
| Long-term implications of computer-assisted detection in high-risk colonoscopy: methodologic and clinical considerations. |
| Self-assembling peptide for bleeding prevention in colorectal endoscopic submucosal dissection: What is the state of evidence? |
| Gut |
| Spatial single-cell omics in liver studies: cautions on metanarrative pitfalls. |
| J Hepatol |
| Limited Clinical Utility of Serum-Based ELISA PEth Compared with Whole Blood LC-MS/MS PEth to Quantify Alcohol Consumption. |